Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.